替莫唑胺联合放疗治疗新诊断的多形性胶质母细胞瘤：系统评价。
Temozolomide and radiotherapy for newly diagnosed glioblastoma multiforme: a systematic review.
机构信息
1Department of Pharmacology, Fujian Medical University, Fuzhou, Fujian, P.R. China.
出版信息
Cancer Invest. 2014 Feb;32(2):31-6. doi: 10.3109/07357907.2013.861474. Epub 2013 Dec 14.
To systematically review the efficacy/safety of radiotherapy/temozolomide (TMZ) vs. radiotherapy for treating glioblastoma (GBM), Medline, Current Contents, and Cochrane database were searched. Five studies were reviewed. Median survival ranged from 9.4 to 19.0 months (radiotherapy/TMZ) vs. 7.3-17.1 months (radiotherapy). Survival ranged from 80.2% to 95.0% (radiotherapy/TMZ) vs. 8.3-84.2% (radiotherapy) at 0.5 years and from 20.0% to 61.1% (radiotherapy/TMZ) vs. 5.0-50.6% (radiotherapy) at 1 year. Median progression-free survival (PFS) ranged from 5.5 to 13.0 months (radiotherapy/TMZ) vs. 4.4-7.6 months (radiotherapy). PFS rates at 0.5 years ranged from 53.9-78.0% (radiotherapy/TMZ) vs. 53.9-78.0% (radiotherapy). Radiotherapy/TMZ provides better survival outcomes than radiotherapy alone in treating GBM.
为了系统地评估放疗联合替莫唑胺（TMZ）与单纯放疗治疗胶质母细胞瘤（GBM）的疗效/安全性，我们检索了 Medline、Current Contents 和 Cochrane 数据库。共纳入了 5 项研究。放疗联合 TMZ 组的中位生存时间为 9.4-19.0 个月，放疗组为 7.3-17.1 个月。放疗联合 TMZ 组的 0.5 年生存率为 80.2%-95.0%，放疗组为 8.3%-84.2%；放疗联合 TMZ 组的 1 年生存率为 20.0%-61.1%，放疗组为 5.0%-50.6%。放疗联合 TMZ 组的中位无进展生存期（PFS）为 5.5-13.0 个月，放疗组为 4.4-7.6 个月。放疗联合 TMZ 组的 0.5 年 PFS 率为 53.9%-78.0%，放疗组为 53.9%-78.0%。与单纯放疗相比，放疗联合 TMZ 可改善 GBM 患者的生存结局。
Zotero 插件